Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.615 USD | +2.84% |
|
+21.52% | +31.22% |
Jul. 02 | Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency | MT |
Jul. 02 | Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.22% | 338M | |
+24.96% | 46.56B | |
+45.49% | 41.67B | |
-0.42% | 41.16B | |
+34.03% | 32.4B | |
+20.72% | 28.18B | |
-6.35% | 28.1B | |
+49.24% | 14.52B | |
+47.88% | 13.74B | |
+1.80% | 12.17B |
- Stock Market
- Equities
- INZY Stock
- News Inozyme Pharma, Inc.
- Inozyme Pharma : Wedbush Adjusts Price Target on Inozyme Pharma to $37 From $35, Keeps Outperform Rating